



Hypoglycemics, Thiazolidinediones (TZDs)

Therapeutic Class Review (TCR)

October 4, 2012

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Suite 201
Cincinnati, Ohio 45242

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.

FDA-APPROVED INDICATIONS

| Drug | Manufacturer | Indication(s) |
|--|-----------------|---|
| TZDs | | |
| pioglitazone (Actos®) ¹ | generic | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
| rosiglitazone (Avandia®) ² | GlaxoSmithKline | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
| TZDs and glimepiride | | |
| pioglitazone/ glimepiride (Duetact™) ³ | Takeda | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea combination or who are not adequately controlled on either agent alone |
| rosiglitazone/ glimepiride (Avandaryl®) ⁴ | GlaxoSmithKline | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with dual rosiglitazone and glimepiride therapy is appropriate |
| TZDs and metformin | | |
| pioglitazone/ metformin (Actoplus Met®) ⁵ | generic | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin combination or who are not adequately controlled on either agent alone |
| pioglitazone/ metformin extended-release (Actoplus Met XR®) ⁶ | Takeda | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin combination or who are not adequately controlled on either agent alone |
| rosiglitazone/ metformin (Avandamet®) ⁷ | GlaxoSmithKline | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with dual rosiglitazone and metformin therapy is appropriate |

OVERVIEW

It is estimated that 25.8 million Americans have diabetes.⁸ The widespread occurrence of obesity supports the projection that cases of diabetes will continue to grow. Diabetes causes a significant economic burden both in terms of direct and indirect costs to society. It is also responsible for increased morbidity and mortality. Adequate glycemic control is crucial to minimize chronic complications including blindness, renal dysfunction resulting in dialysis or transplantation, and nontraumatic amputations.⁹

Three metabolic defects are responsible for the progression to type 2 diabetes mellitus: peripheral insulin resistance, impaired β -cell function, and increased hepatic glucose production.¹⁰ The thiazolidinediones (TZDs) work by decreasing insulin resistance. Combination products of TZDs with metformin and glimepiride are available and may improve adherence for those patients requiring combination therapy.

The 2009 American Diabetes Association (ADA) consensus algorithm recommends a hemoglobin A1c (HbA1c) less than seven percent and divides its treatment recommendations into tier one interventions and tier two interventions.¹¹ Tier one interventions are those treatment recommendations that are considered well-validated, most clinically- and cost-effective, and represent

the preferred pathway of treatment for patients with type 2 diabetes. Tier two interventions are less well-validated options and should be used only in select patient populations. The initiation of metformin concurrent with lifestyle modifications at the time of diagnosis continues to be recommended by the ADA, and it is considered step one of three of the tier one recommendations. If metformin therapy and lifestyle interventions fail to achieve or sustain glycemic goals, step two of the tier one recommendations proposes the addition of either basal insulin or a sulfonylurea. In select patient populations who do not respond adequately to the step one interventions and in whom hypoglycemia should be avoided, the clinician may employ a tier two intervention by adding pioglitazone (Actos). The use of rosiglitazone (Avandia) is not a tier one or two recommendation in the treatment algorithm.

The 2012 ADA Standards of Medical Care in Diabetes position statement recommends for the treatment of type 2 diabetes metformin therapy along with lifestyle interventions at the time of diagnosis, unless metformin is contraindicated.¹² In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, insulin therapy should be considered, with or without additional agents. If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over three to six months, a second oral agent, a GLP-1 receptor agonist, or insulin should be added.

The 2009 Consensus Panel of the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) issued an algorithm for glycemic control in patients with type 2 diabetes.¹³ In order to minimize the risk of diabetes related complications, the goal of therapy is to achieve an HbA1c of 6.5 percent or less, with recognition of the need for individualization to minimize the risks of hypoglycemia. Patients are stratified based on their current HbA1c levels and whether they are receiving treatment or drug-naïve. Monotherapy, dual therapy, and triple therapy, including eight major classes of oral medications (biguanides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, incretin mimetics, thiazolidinediones, alpha glucosidase inhibitors (AGIs), sulfonylureas, meglitinides, and bile acid sequestrants) and insulin therapy (basal, premixed, and multiple daily injections), with or without orally administered medications are included in the algorithm. For the patient with an HbA1c level within the range of 6.5 percent to 7.5 percent, it is possible that a single agent (e.g., metformin, TZD, DPP-4 Inhibitor, or AGI) might achieve the HbA1c goal of 6.5 percent. Because of its safety and efficacy, metformin is the cornerstone of monotherapy and is usually the most appropriate initial choice for monotherapy unless there is a contraindication. The TZDs require several weeks to achieve maximal benefit; likewise, their effects decline slowly after they have been discontinued. In patients with clear evidence of insulin resistance or the clinical “metabolic syndrome” and in patients with nonalcoholic fatty liver disease, TZDs may be preferred. For the patient with an HbA1c level within the range of 7.6 percent to 9.0 percent, dual therapy may be necessary. As a result of its safety and efficacy, metformin should be the cornerstone of dual therapy for most patients. When metformin is contraindicated, then a TZD may be used. Because metformin or a TZD will serve as an insulin sensitizer, the second component of the dual therapy is usually an incretin mimetic, DPP-4 inhibitor, meglitinides, or sulfonylurea. When dual therapy is insufficient, then triple therapy or insulin may be needed. The choices of medications are prioritized according to safety, risk of hypoglycemia, efficacy, simplicity, anticipated degree of patient adherence, and cost.

According to the AACE 2012 guidelines, antidiabetic therapy should generally target an HbA1c level of 6.5 percent or less for most nonpregnant adults.¹⁴ Glucose targets should be individualized and take into account residual life expectancy, duration of disease, CVD risk factors, and comorbid conditions;

and should also consider the patient's psychological, social, and economic status. The aim of antidiabetic therapy is the prevention of microvascular and macrovascular complications achieved without substantial hypoglycemia. The progression of microvascular complications is benefitted by strict glycemic control. These guidelines support the choice of therapeutic agents as described in the AACE/ACE 2009 consensus statement.

Key points in the 2012 Position Statement by the ADA and European Association for the Study of Diabetes (EASD) on the management of hyperglycemia in type 2 diabetes include: glycemic targets and glucose-lowering therapies must be individualized; metformin is the optimal first-line drug unless contraindications exist; after metformin, there are limited data to guide therapy, but combination therapy with an additional one to two oral or injectable agents is reasonable, aiming to minimize side effects where possible; and comprehensive cardiovascular risk reduction must should be a major focus of therapy.¹⁵ If metformin fails to produce the target HbA1c after three months of therapy either a TZD, sulfonylurea, DPP-4 inhibitor, GLP-1 receptor agonist or insulin should be added. If target HbA1c is still not achieved after an additional three months, then an agent from a different group listed should be added. Therapy should be individualized based on the needs, preferences, and tolerances of each patient. Patients with type 2 diabetes are at increased risk of cardiovascular morbidity and mortality; therefore aggressive management of cardiovascular risk factors (blood pressure and lipid therapy, antiplatelet treatment, and smoking cessation) should be part of multifactorial risk reduction approach.

TZDs have been reported to increase HDL-C (and pioglitazone lowers triglycerides), lower blood pressure, reduce markers of inflammation, reduce hepatic steatosis, decrease carotid and coronary artery thickening, and may help prevent central nervous system insulin resistance–related cognitive dysfunction.¹⁶ However, TZDs can have adverse effects such as fluid retention, and therefore should be used with caution in patients with peripheral vascular disease and are contraindicated in patients with New York Heart Association class 3 and 4. Use of rosiglitazone has been restricted in the US due to concerns of a possible increase in CVD risk.

PHARMACOLOGY

The TZDs bind and activate peroxisome proliferator-activated receptor gamma (PPAR- γ) in skeletal muscle, adipose tissue, and the liver, resulting in improved insulin action by enhancing the sensitivity of peripheral muscle glucose uptake and possibly reducing hepatic glucose production.^{17, 18} The TZDs require the presence of insulin.

Metformin (Glucophage[®]), a biguanide, decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.^{19, 20}

Glimepiride (Amaryl[®]) is a member of the sulfonylureas, which enhance response of beta cells in the pancreatic islet to glucose, in turn stimulating the release of insulin.^{21, 22}

TZDs and sulfonylureas primarily affect fasting blood glucose. Metformin affects both fasting and postprandial blood glucose levels. The reduction of HbA1c due to any of these agents is expected to be approximately 1 percent to 1.5 percent. The duration of glycemic control with TZDs appears to be maintained over periods up to five to six years. Glucose lowering is maximal at six months with sulfonylureas, and glucose levels return towards baseline at about three years. Metformin appears intermediate in duration in its glucose lowering effects.^{23, 24}

PHARMACOKINETICS

| Drug | Bioavailability (%) | Half-Life (hr) | Metabolites | Excretion (%) |
|---------------------------------------|---------------------|--|---|--|
| glimepiride (Amaryl) ²⁵ | 100 | 5-9.2 | Two inactive metabolites | renal: 60 feces: 40 |
| metformin (Glucophage) ²⁶ | 50-60 | 6.2 | None | renal: >90 |
| pioglitazone (Actos) ²⁷ | -- | 3-7 (parent); 16-24 (parent plus metabolites) | M-II, M-III, M-IV (active in animal models) | renal: 15-30 (as metabolites) feces: majority of dose |
| rosiglitazone (Avandia) ²⁸ | 99 | 3-4 | Yes, inactive | renal: 64 feces: 23 |

In bioequivalence studies of all combination products, both the TZD and the metformin or glimepiride component were bioequivalent to the single agents administered together.^{29, 30, 31, 32}

CONTRAINDICATIONS/WARNINGS^{33, 34, 35, 36, 37, 38}

TZD-containing products have boxed warnings stating that TZD use can cause or exacerbate congestive heart failure in some patients. After initiation of TZD therapy, and after dose increases, patients should be observed carefully for signs and symptoms of heart failure including excessive, rapid weight gain, dyspnea, and/or edema. If these signs and symptoms develop, heart failure should be managed according to the current standards of care. Discontinuation or dose reduction of TZD must be considered. The initiation of TZD therapy in patients with NYHA Class III or IV heart failure is contraindicated.

Rosiglitazone contains an additional boxed warning for the possibility of increased risk of myocardial ischemic events such as angina or myocardial infarction. A meta-analysis of 42 clinical studies (mean duration six months; 14,237 total patients), most of which compared rosiglitazone to placebo, showed rosiglitazone to be associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction.³⁹ Three other studies (mean duration 41 months; 14,067 total patients), comparing rosiglitazone to some other approved oral antidiabetic agents or placebo, have not confirmed or excluded this risk. In its entirety, the available data on the risk of myocardial ischemia are inconclusive. This risk appeared higher in patients taking nitrates or insulin. Taking rosiglitazone with insulin or nitrates is not recommended.

A science advisory was released in February 2010 by the American Heart Association and the American College of Cardiology Foundation to summarize the available evidence about TZDs and cardiovascular risk with a focus on ischemic heart disease (IHD).⁴⁰ The authors concluded that an association between rosiglitazone and IHD outcomes has not yet been firmly established. However, sufficient evidence has emerged to raise concerns about a potential adverse effect and justifies the black box warning for rosiglitazone. Also, they stated that the majority of published studies do not suggest an increased hazard for IHD events in pioglitazone-treated patients.

In September 2010, as a result of review of cardiovascular safety data, including data from the long-term clinical study, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD), the FDA notified healthcare professionals and patients that significant restrictions

are to apply to the use of rosiglitazone (Avandia) in patients with Type 2 diabetes mellitus who cannot adequately control diabetes on other medications.⁴¹ In May 2011, the FDA outlined the risk evaluation and mitigation strategy (REMS) which applies to all rosiglitazone containing products. Under the REMS, healthcare providers and patients must enroll in a special program in order to prescribe and receive these drugs. The REMS, called the Avandia-Rosiglitazone Medicines Access Program, limits the use of rosiglitazone medicines to patients already being successfully treated with these medicines and patients whose blood sugar cannot be controlled with other anti-diabetic medicines and who, after consulting with their healthcare provider, do not wish to use pioglitazone-containing medicines.⁴² As of November 18, 2011, rosiglitazone medicines are no longer available through retail pharmacies.

In June 2011, the FDA issued a safety announcement that the use of pioglitazone (Actos) for more than one year may be associated with an increased risk of bladder cancer.⁴³ Consequently, pioglitazone should not be used in patients with active bladder cancer and should be used with caution in those with a prior history of bladder cancer. The benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of bladder cancer.⁴⁴

Labeling for rosiglitazone/glimepiride (Avandaryl) and pioglitazone/glimepiride (Duetact) contains a warning for increased risk of cardiovascular mortality due to the sulfonylurea component. In addition, the glimepiride component may cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. A non-sulfonylurea should be considered as an alternative in these patients.

Any product containing metformin is contraindicated in patients with any of the following: renal disease or renal dysfunction (serum creatinine >1.5 mg/dL for males and >1.4 mg/dL for females), acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma), pregnancy, or known hypersensitivity to metformin or other ingredients in the drug formulation.

Lactic acidosis is a rare, but potentially fatal, complication of metformin therapy. The risk is greater for patients experiencing sepsis, dehydration, hypoxemia, hypoperfusion, hepatic/renal impairment, or those who consume excess alcohol. Metformin should be used with caution in patients with renal insufficiency or patients undergoing radiologic procedures who need intravenous iodinated contrast agents.

Use of glimepiride, metformin, pioglitazone, or rosiglitazone is contraindicated in patients with known hypersensitivity to these products or any of their components.

Precautions^{45, 46, 47, 48, 49, 50}

For pioglitazone and rosiglitazone, liver function tests are recommended at the start of therapy, then periodically thereafter at the discretion of the physician. This recommendation extends to all products in combination with TZDs. If the alanine aminotransferase (ALT) level rises, it should be monitored closely. If ALT exceeds 2.5 to three times the upper limit of normal, the drug should be discontinued.

Dose-related weight gain has been observed in patients taking pioglitazone and rosiglitazone either alone or in combination with other hypoglycemic agents.

TZDs should be used with caution in patients with edema. Edema was reported more frequently in patients treated with pioglitazone or rosiglitazone than placebo; a dose related effect has been observed.

Dose-related decreases in mean hemoglobin and hematocrit may occur in adults taking pioglitazone or rosiglitazone either alone or in combination with other hypoglycemic agents.

In premenopausal anovulatory women, the initiation of therapy with pioglitazone or rosiglitazone may cause ovulation; therefore, patients may be at an increased risk for pregnancy. Adequate contraception is recommended.

Do not use pioglitazone or rosiglitazone to treat type 1 diabetes or diabetic ketoacidosis.

Caution should be used with patients experiencing hypoxic states or undergoing surgical procedures and patients with hepatic impairment or with excessive alcohol intake. Due to the age-related decline of renal function, do not titrate metformin to the upper dosage range in elderly patients (>80 years of age) even for patients with serum creatinine levels within the normal range.

In PROactive, a randomized trial with patients with type 2 diabetes, an increased incidence of bone fractures was noted in pioglitazone patients (5.1 percent versus 2.5 percent for patients taking placebo).⁵¹ This difference was noted after the first year of treatment and remained during the course of the study. The majority of fractures were nonvertebral (lower and upper limb), and no increase was seen in men taking pioglitazone.

In two three-year trials in which pioglitazone was compared to placebo or glyburide, there were increased reports of bladder cancer in patients taking pioglitazone (44 percent versus 14 percent for patients taking glyburide or placebo). There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, pioglitazone should not be used in patients with active bladder cancer and the benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of bladder cancer.⁵²

Based on a review of the safety data from the ADOPT study, rosiglitazone labeling includes mention of an increased number of arm, hand, and foot fractures among women taking rosiglitazone for newly diagnosed type 2 diabetes.⁵³ The fracture rate was 2.74 per 100 patient years for the 645 women treated with rosiglitazone versus 1.54 per 100 patient-years for the 590 women in the metformin arm and 1.29 per 100 patient-years for 605 women treated with glyburide. The increase in fractures was seen in the humerus, hand, and foot for women taking rosiglitazone; there was no increase in hip or spine fractures, usually associated with postmenopausal osteoporosis.

Macular edema has been reported in post-marketing experience in diabetic patients on TZD therapy. Some patients had improvement in their macular edema after discontinuation of TZD therapy. It is unknown whether or not there is a causal relationship between TZDs and macular edema. Patients with diabetes should have regular eye examinations by an ophthalmologist and should be promptly referred to an ophthalmologist if any kind of visual symptom is reported.

Risk Evaluation and Mitigation Strategy (REMS)^{54, 55, 56, 57, 58, 59, 60}

A REMS program that includes a Medication Guide and a timeline for submission of assessments will be included with all prescriptions for rosiglitazone-containing products, to inform patients about the serious risks associated with its use. The REMS requirement for pioglitazone-containing products was eliminated, however the Medication Guide is maintained as part of the approved labeling.

Because of the potential increased risk of myocardial infarction, rosiglitazone and rosiglitazone-containing products are available only through a restricted distribution program called the Avandia-

Rosiglitazone Medicines Access. Both prescribers and patients must enroll in the program to be able to prescribe or receive rosiglitazone, respectively. These products will be available only from specially certified pharmacies participating in the program. As part of the program, prescribers will be educated about the potential increased risk of myocardial infarction and the need to limit the use of rosiglitazone to eligible patients (e.g. already taking rosiglitazone or unable to achieve glycemic control on other medications).

DRUG INTERACTIONS^{61, 62, 63, 64, 65, 66}

Pioglitazone (Actos) and rosiglitazone (Avandia) are predominantly metabolized by CYP2C8. If an inhibitor or inducer of CYP2C8 is started or stopped during treatment with either agent, changes in treatment may be needed based on clinical response. Additionally to a much lesser extent, rosiglitazone is also metabolized by CYP2C9, and pioglitazone is metabolized by CYP3A4.

Exercise caution when using with drugs that are known to exacerbate hyperglycemia.

Cationic drugs such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin that are eliminated by renal tubular secretion have a theoretical potential interaction with metformin by competing for common renal tubular transport systems. No specific dosing changes are recommended. Increased metformin plasma concentrations are seen with concurrent administration of cimetidine, furosemide, and nifedipine. No specific dosing changes are recommended.

ADVERSE EFFECTS

| Drug | Headache | Edema | Myalgia/ Fatigue | Anemia | Hyperglycemia | Diarrhea | Hypoglycemia |
|---|--------------|--------------|---------------------|--------------|---------------|----------------|--------------|
| glimepiride (Amaryl) ⁶⁷ n=746 | 1.5 | nr | nr | nr | nr | <1 | 0.9 to 1.7 |
| metformin (Glucophage) ⁶⁸ n=141 | 5.7 (4.8) | nr | 1-5 | nr | nr | 53.2 (11.7) | 1 to 5 |
| pioglitazone (Actos) ⁶⁹ | 9.1 (6.9) | 4.8 (1.2) | 5.4 (2.7) | ≤2 | 5.1 (8.1) | nr | reported |
| rosiglitazone (Avandia) ⁷⁰ n=2,526 | 5.9 (5) | 4.8 (1.3) | 3.6 (5) | 1.9 (0.7) | 3.9 (5.7) | 2.3 (3.3) | 0.6 (0.2) |

Adverse effects are reported as a percentage. Adverse effects data are obtained from prescribing information and therefore, should not be considered comparative or all-inclusive. Incidences in parentheses are placebo. nr = not reported.

Adverse effects reported in the labeling for Actoplus Met, Actoplus Met XR, Avandaryl, Avandamet, and Duetact do not reflect the specific combination product.

Edema and CHF

The incidence of edema with the combination of pioglitazone and insulin was 15.3 percent and with insulin and placebo was seven percent. In a 16-week study, 1.1 percent of patients receiving insulin and pioglitazone developed heart failure, and no patients on insulin therapy alone developed heart failure.⁷¹

Combined and peripheral edema was reported more frequently in patients taking combination pioglitazone/metformin therapy (six percent) than metformin/placebo (2.5 percent).⁷² Edema was also higher in patients receiving rosiglitazone/metformin therapy (4.4 percent) than metformin/placebo (2.2 percent).

The incidence of edema with rosiglitazone in combination with insulin was 14.7 percent whereas insulin alone was 5.4 percent in a 26-week study.⁷³ New onset of heart failure was one percent with insulin, two percent with rosiglitazone 4 mg with insulin, and three percent with rosiglitazone 8 mg with insulin.

Hypoglycemia

Hypoglycemia was reported more frequently in patients taking combination rosiglitazone/metformin therapy (three percent) than rosiglitazone (0.6 percent) or metformin (1.3 percent) monotherapy.⁷⁴

Anemia

Anemia was also reported in a greater number of patients taking combination rosiglitazone/metformin therapy (7.1 percent) compared to rosiglitazone (1.9 percent) or metformin (2.2 percent) monotherapy. Anemia was reported in less than two percent of patients taking pioglitazone/metformin therapy.⁷⁵

Effect on Cholesterol/Triglycerides

| Drug | Total-Cholesterol | HDL Cholesterol | LDL Cholesterol | Triglycerides |
|--|--------------------------------------|------------------------|------------------------|----------------------|
| pioglitazone (Actos) ⁷⁶ versus placebo | ↑ 3.3-6.4%* ↑ 4.4% | ↑ 12.2-19.1% ↑ 8.1% | ↑ 5.2-7.2%* ↑ 4.8% | ↓ 9.0-9.6% ↑ 4.8% |
| rosiglitazone (Avandia) ⁷⁷ versus placebo | ↑ (percent increase not reported) | ↑ 11.4-14.2% ↑ 8% | ↑ 14.1-18.6% ↑ 4.8% | variable |

*not significantly different from placebo

SPECIAL POPULATIONS^{78, 79, 80, 81, 82, 83}

Pediatrics

Although metformin is approved for use in children ages 10 and older, safety and effectiveness have not been established for pioglitazone (Actos) or rosiglitazone (Avandia) or their combinations with metformin in pediatric patients. Glimepiride also has not been studied in this population, nor has its combination with pioglitazone or rosiglitazone.

Pregnancy

All pioglitazone- and rosiglitazone- containing products are Pregnancy Category C.

According to ADA and AACE guidelines, HbA1c goal of 6.0 percent or less is appropriate in pregnant women, only if it can be safely achieved.^{84, 85}

Ethnic groups

A randomized, double-blind, placebo-controlled, parallel-group study was performed to determine the efficacy and tolerability of the addition of rosiglitazone to a regimen of glyburide once daily in African-American and Hispanic-American patients with type 2 diabetes previously inadequately controlled with at least two months of sulfonylurea monotherapy.⁸⁶ Patients were assigned to receive treatment with glyburide 10 or 20 mg daily plus rosiglitazone 8 mg or placebo daily for 24 weeks. The primary efficacy endpoint was the change from baseline in HbA1c after 24 weeks of treatment. A total of 245 patients (101 African-Americans, 144 Hispanic-Americans) were enrolled. In the overall study population, treatment with glyburide/rosiglitazone was associated with a significantly greater mean reduction from baseline in HbA1c compared with glyburide/placebo (between-group difference: -1.4 percent; $p < 0.001$). When assessed by ethnicity, HbA1c values were significantly reduced with glyburide/rosiglitazone compared with glyburide/placebo in African-American patients and in Hispanic-American patients (both $p < 0.001$). With glyburide/rosiglitazone, 17.6 percent of African-American patients and 25.8 percent of Hispanic-American patients achieved HbA1c < 7 percent, compared with 4.5 and 1.4 percent of glyburide/placebo patients, respectively. The most frequently reported adverse events with glyburide/rosiglitazone were edema and weight increase.

DOSAGES^{87, 88, 89, 90, 91, 92, 93, 94}

| Drug | Initial dose | Maintenance dose | Availability |
|---|---|-------------------------------------|---|
| TZDs | | | |
| pioglitazone (Actos) | 15-30 mg daily | 15-45 mg daily | 15, 30, 45 mg tablets |
| rosiglitazone (Avandia) | 4 mg daily OR 2 mg twice daily | 2-4 mg twice daily OR 8 mg daily | 2, 4, 8 mg tablets |
| TZDs and glimepiride | | | |
| pioglitazone/glimepiride (Duetact) | Prior therapy with glimepiride or pioglitazone: 30 mg/2 mg or 30 mg/4 mg once daily with the first meal of the day Maximum daily dose: 45 mg/8 mg | | 30 mg/2 mg, 30 mg/4 mg tablets |
| rosiglitazone/glimepiride (Avandaryl) | 4 mg/1 mg once daily with the first meal of the day (consider 4 mg/2 mg if patient was on prior TZD or sulfonylurea therapy) Maximum daily dose: 8 mg/4 mg | | 4 mg/1 mg, 4 mg/2 mg, 4 mg/4 mg, 8 mg/2 mg, 8 mg/4 mg tablets |
| TZDs and metformin | | | |
| pioglitazone/metformin (Actoplus Met) | 15 mg/500 mg or 15 mg/850 mg tablets once or twice daily with food Max daily dose: 45 mg/2,550 mg administered in divided doses with food | | 15 mg/500 mg, 15 mg/850 mg tablets |
| pioglitazone/metformin extended-release (Actoplus Met XR) | 15 mg/1000 mg or 30 mg/1000 mg tablets once daily with evening meal Max daily dose: 45 mg/2000 mg administered once daily with evening meal | | 15 mg/1000 mg, 30 mg/1000 mg tablets |
| rosiglitazone/metformin (Avandamet) | Prior therapy with metformin 1,000 mg/day: 2 mg/500 mg twice daily | | 2 mg/500 mg, 4 mg/500 mg, 2 mg/1,000 mg, 4 mg/1,000 mg tablets |
| | Prior therapy with metformin 2,000 mg/day: 2 mg/1,000 mg twice daily | | |
| | Prior therapy with rosiglitazone 4 mg/day: 2 mg/500 mg twice daily | | |
| | Prior therapy with rosiglitazone 8 mg/day: 4 mg/500 mg twice daily | | |

Pioglitazone and rosiglitazone may be taken without regard to meals. No dosage adjustment is required in patients with renal impairment.

Therapy with pioglitazone or rosiglitazone should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT > 2.5 times the upper limit of normal).

CLINICAL TRIALS

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all brand names in this class. Randomized, comparative, controlled trials performed in the United States comparing agents within this class in an outpatient setting for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance. In countries outside of the US, blood glucose values are typically reported in mmol/L. For those studies reporting blood glucose values in mmol/L, the value in mg/dL can be estimated by multiplying the mmol/L value by 18.

Very few comparative clinical trials of the combination products are available at this time. There is one trial comparing a fixed-dose combination product to its component ingredients.

pioglitazone (Actos) and placebo

A total of 408 patients with type 2 diabetes were randomized in a multicenter, double-blind, placebo-controlled trial.⁹⁵ Patients had HbA1c >7 percent and fasting plasma glucose (FPG) >140 mg/dL, and were randomized to receive placebo or pioglitazone 7.5, 15, 30, or 45 mg daily for 26 weeks. Patients treated with 15, 30, or 45 mg pioglitazone had significant mean decreases in HbA1c (-1.0 to -1.6 percent difference from placebo) and FPG (-39.1 to -65.3 mg/dL difference from placebo). The decreases in FPG were observed as early as the second week of therapy; maximal decreases occurred after 10 to 14 weeks and were maintained until the end of therapy. The subset of patients naïve to therapy had greater improvements in HbA1c and FPG (difference from placebo of -2.55 percent and -79.9 mg/dL for the 45 mg group, respectively) compared with previously treated patients. The overall adverse event profile of pioglitazone was similar to that of placebo, with no evidence of hepatotoxicity or ALT elevations.

Patients (n=197) with type 2 diabetes, HbA1c >8 percent, and FPG >7.7 mmol/L were enrolled in a 23-week, double-blind trial and randomized to receive either placebo or pioglitazone 30 mg daily.⁹⁶ Efficacy parameters included HbA1c and FPG. Compared with placebo, pioglitazone significantly (p=0.0001) reduced HbA1c (-1.37 percent) and FPG (-3.19 mmol/L). The overall adverse event profile of pioglitazone was similar to that of placebo, with no evidence of drug-induced elevations of ALT concentrations or hepatotoxicity.

A double-blind, randomized, placebo-controlled study involved daily administration of pioglitazone 15 or 30 mg or placebo daily in patients with type 2 diabetes (n=251) for 26 weeks.⁹⁷ HbA1c was reduced by -0.92 and -1.05 percent in the pioglitazone groups, respectively, and FBG was reduced by -34.3 and -

36.0 mg/dL, respectively, compared with placebo. Both doses of pioglitazone significantly reduced postprandial blood glucose levels at all visits (-163 and -165 mg/dL/hour, respectively) compared with an increase of 47.7 mg/dL/hour on placebo. The type and frequency of adverse events were similar in all treatment groups.

pioglitazone (Actos) and insulin

In a 16-week, double-blind, multicenter study, 566 patients currently on a stable insulin regimen for at least 30 days who continued to have an HbA1c >8 percent were randomized to receive daily placebo or pioglitazone 15 mg or 30 mg.⁹⁸ At the end of treatment, patients receiving pioglitazone 15 mg or 30 mg had mean decreases in HbA1c (-1 and -1.3 percent, respectively; $p < 0.0001$) and FPG (-34.5 and -48 mg/dL, respectively; $p < 0.0001$) that were significantly lower than baseline and the placebo group. The 15 mg and 30 mg pioglitazone groups had significant increases in HDL-C, while the 30 mg group showed significant mean reductions in triglyceride levels compared to placebo. The incidences of weight increase, hypoglycemia, and edema were higher among patients receiving insulin plus pioglitazone.

pioglitazone (Actos), metformin (Glucophage), and insulin

In a multicenter, double-blind study, 222 patients with HbA1c >8 percent at screening were given titrated insulin therapy and then were randomly assigned to 20-week treatment with pioglitazone or placebo in combination with insulin, with or without concurrent metformin therapy.⁹⁹ More than 98 percent of patients were taking metformin prior to and during the study. Pioglitazone significantly reduced insulin dose requirements two weeks after treatment initiation ($p < 0.05$). At the end of the study, pioglitazone reduced daily insulin dosages by 12 units ($p < 0.001$). Relative to placebo, pioglitazone reduced daily insulin dosages by 12.7 units, while improving mean HbA1c levels (pioglitazone -1.6 versus placebo -1.4 percent; $p = \text{NS}$). More pioglitazone-treated patients experienced edema and weight gain than placebo-treated patients.

pioglitazone/metformin (Actoplus Met) versus pioglitazone (Actos) versus metformin (Glucophage)

In a double-blind, randomized, parallel-group, controlled, 24-week study, 600 patients with type 2 diabetes were randomized to receive pioglitazone 15 mg/metformin 850 mg twice daily, pioglitazone 15 mg twice daily, or metformin 850 mg twice daily.¹⁰⁰ The primary endpoint was change from baseline in HbA1c of pioglitazone/metformin combination therapy compared with pioglitazone and metformin monotherapy. Secondary endpoints included change from baseline in FPG, fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR). Safety and tolerability of pioglitazone/metformin combination therapy and its individual components were also evaluated. Patients with HbA1c greater than 8.6 percent at baseline showed the greatest decrease in HbA1c with the fixed-dose combination product (-1.83 percent; $p < 0.0001$) versus with monotherapy pioglitazone (-0.96 percent) and with monotherapy metformin (-0.99 percent). In addition, 63.8 percent of patients using the fixed-dose combination achieved HbA1c of 7 percent or less versus 46.9 percent and 38.9 percent of patients receiving pioglitazone and metformin monotherapy, respectively. The decrease from baseline FPG was significantly larger in the pioglitazone/metformin fixed-dose combination group (-39.9 mg/dL) ($p < 0.01$) compared with either monotherapy. Also, the decrease in mean HOMA-IR was greatest with the combination therapy group. Overall, treatment with combination therapy demonstrated greater efficacy than its individual components. The fixed-dose combination was well

tolerated, with reduced or similar adverse event rates compared with each individual monotherapy. This study was funded by the manufacturer of the fixed dose combination product.

pioglitazone (Actos), rosiglitazone (Avandia), and glimepiride (Amaryl)

A 12-month, multicenter, double-blind, randomized, controlled, parallel-group trial assessed 91 patients with type 2 diabetes and metabolic syndrome.¹⁰¹ All patients had poor glycemic control or experienced one or more adverse effects with diet and oral hypoglycemic agents such as sulfonylureas or metformin. All patients received a fixed oral dose of glimepiride 4 mg/day for 12 months. Patients also were randomized to receive pioglitazone 15 mg once daily or rosiglitazone 4 mg once daily for 12 months. Patients in both groups experienced significant increases in mean BMI at 12 months compared with baseline (4.92 and 6.17 percent, respectively; $p < 0.05$). At 12 months, a 1.3 percent reduction in mean values for HbA1c ($p < 0.01$), 19.3 percent in FPG ($p < 0.01$), and 16.3 percent in postprandial plasma glucose ($p < 0.01$) were observed; no significant differences were found between treatment groups. Although the glimepiride/pioglitazone group experienced a significant improvement at 12 months in almost all variables of lipid metabolism from baseline, the glimepiride/rosiglitazone group experienced a significant increase in most lipid-related risk factors for cardiovascular disease. Of the 87 patients who completed the study, 6.7 percent of patients in the glimepiride/pioglitazone group and 11.9 percent of patients in the glimepiride/rosiglitazone group had transient, mild to moderate adverse events that did not cause withdrawal from the trial.

pioglitazone (Actos), rosiglitazone (Avandia), glimepiride (Amaryl), and metformin (Glucophage)

A randomized, double-blind, placebo-controlled, parallel-group, two-arm study enrolled 170 patients with type 2 diabetes.¹⁰² Patients received glimepiride 2 mg (titrated to effect) or placebo in combination with an established regimen of immediate- or extended release metformin and rosiglitazone or pioglitazone for 26 weeks. The primary efficacy outcome was the change in HbA1c from baseline. HbA1c was significantly improved at endpoint with glimepiride combination therapy compared with placebo (-1.31 versus -0.33 percent, respectively; $p < 0.001$). Of the patients who received glimepiride, 62.2 percent achieved an HbA1c value of < 7 percent, compared with 26 percent of patients receiving placebo ($p < 0.001$). At endpoint, the glimepiride combination significantly lowered FPG (-37.4 mg/dL; $p < 0.001$), as well. Clinically significant adverse events, laboratory abnormalities, and rates of severe hypoglycemia were similar between treatment groups. The overall incidence of hypoglycemia, however, was 51.2 percent in the glimepiride group and 8.3 percent in the placebo group ($p < 0.001$).

rosiglitazone (Avandia) and placebo

Three hundred and sixty-nine patients with type 2 diabetes were enrolled in a double-blind, parallel-group, placebo-controlled study.¹⁰³ Patients were randomly assigned to receive placebo or rosiglitazone at doses of 4, 8, or 12 mg daily. At eight weeks, FPG decreased significantly in the rosiglitazone 4 mg, 8 mg, and 12 mg groups (-0.9, -2.0 and -1.7 mmol/L; $p = 0.0003$, $p < 0.0001$, and $p < 0.0001$, respectively) compared with placebo (+0.4 mmol/L). Improvements in FPG were seen for rosiglitazone 4 and 8 mg groups, but the 12 mg/day dose produced no additional improvement. The overall incidence of adverse events was similar in all treatment groups.

In a double-blind study, 959 patients were randomized to placebo or rosiglitazone 4 mg or 8 mg for 26 weeks. The primary measure of efficacy was change in the HbA1c concentration.¹⁰⁴ Rosiglitazone produced reductions in HbA1c of -0.8 to -1.5 percent compared with placebo. Approximately 33 percent of drug-naïve patients treated with rosiglitazone achieved HbA1c <7 percent at study end. The proportions of patients with at least one adverse event were comparable among the rosiglitazone and placebo groups, with no evidence of hepatotoxicity in any treatment group.

After a four-week placebo run-in period, 493 patients with type 2 diabetes were randomized in a double-blind manner to receive rosiglitazone 2 mg or 4 mg or placebo twice daily for 26 weeks.¹⁰⁵ The primary end point was change in HbA1c. Rosiglitazone 2 and 4 mg twice daily decreased mean HbA1c relative to placebo by -1.2 and -1.5 percentage points, respectively and reduced FPG concentrations relative to placebo by -3.22 and -4.22 mmol/L, respectively. There was no increase in adverse events with rosiglitazone.

After a two-week placebo run-in phase, 303 patients with type 2 diabetes were randomly assigned in double-blind fashion to eight weeks of treatment with placebo or 2, 4, or 6 mg of rosiglitazone twice daily (FDA-approved maximum dose is 8 mg daily).¹⁰⁶ All rosiglitazone doses significantly reduced FPG compared with baseline and showed significantly reduced peak postprandial glucose concentrations compared with baseline ($p < 0.001$) and with placebo ($p < 0.0001$). Rosiglitazone 4 and 6 mg twice daily regimens prevented increases in HbA1c that were observed in the placebo group. The proportion of patients with one or more adverse event was similar in all four treatment groups with no evidence of hepatotoxicity.

rosiglitazone (Avandia), glyburide (Micronase[®], Diabeta[®]), and metformin (Glucophage)

The efficacy and safety of adding rosiglitazone to an established regimen of glyburide/metformin in patients with type 2 diabetes who had not achieved adequate glycemic control (HbA1c between seven and ten percent) were evaluated.¹⁰⁷ Following an open-label, lead-in phase, 365 patients randomly received rosiglitazone 4 mg once daily or placebo in a double-blind manner. Based on glycemic response, rosiglitazone dose was maintained or increased to 4 mg twice daily. After 24 weeks, therapy with glyburide/metformin plus rosiglitazone resulted in a greater reduction (-1 percent, $p < 0.001$) in HbA1c levels compared with combination therapy that included placebo (+0.1 percent). A larger proportion of patients (42 versus 14 percent) in the triple combination group attained HbA1c levels less than seven percent. The difference in FBG levels between groups was -48 mg/dL ($p < 0.001$), favoring glyburide/metformin plus rosiglitazone. Adverse events of rosiglitazone reflected those reported in similar studies.

rosiglitazone (Avandia) and glipizide (Glucotrol)

A total of 227 patients with type 2 diabetes who were being treated with submaximal doses of sulfonylureas were randomized to receive rosiglitazone 4 mg or placebo daily in combination with glipizide 10 mg twice daily for two years in a double-blind, parallel-group study.¹⁰⁸ Rosiglitazone/glipizide significantly decreased HbA1c, FPG, insulin resistance, plasma free fatty acids, and medical care utilization and improved treatment satisfaction compared with glipizide alone.

rosiglitazone (Avandia) and insulin

Three hundred nineteen patients with type 2 diabetes with mean baseline HbA1c >7.5 percent and taking insulin twice daily were randomized in a double-blind manner to 26 weeks of additional treatment with rosiglitazone 4 or 8 mg daily or placebo.¹⁰⁹ Insulin dose could be decreased for safety reasons. The primary endpoint was reduction of HbA1c from baseline. By intent-to-treat analysis, treatment with rosiglitazone plus insulin resulted in a mean reduction from baseline in HbA1c of -1.2 percent ($p<0.0001$), with a 12 percent mean reduction of insulin dosage. Serious adverse events did not differ among groups.

rosiglitazone (Avandia) and metformin (Glucophage)

The efficacy of the combination of metformin and rosiglitazone compared to metformin alone was evaluated in 348 patients with type 2 diabetes who were inadequately controlled on metformin alone.¹¹⁰ Patients were randomized in a double-blind fashion to metformin 2,500 mg daily plus placebo, metformin 2,500 mg plus rosiglitazone 4 mg daily, or metformin 2,500 mg daily plus rosiglitazone 8 mg daily for 26 weeks. HbA1c, FPG, insulin sensitivity, and β -cell function improved significantly with the combination therapy in a dose-dependent manner. The mean HbA1c decrease was one percent in the rosiglitazone 4 mg group and 1.2 percent in the rosiglitazone 8 mg group. Twenty-eight percent of patients in the rosiglitazone 8 mg group achieved HbA1c less than seven percent. Dose-dependent increases in body weight and lipid profiles were observed. Adverse effects were similar in all groups.

The efficacy and safety of rosiglitazone 2 mg or 4 mg twice daily in combination with metformin 2,500 mg daily were evaluated in 116 patients whose type 2 diabetes was inadequately controlled with metformin alone.¹¹¹ The randomized, double-blind, placebo-controlled study was conducted for 26 weeks. Mean HbA1c levels decreased significantly from baseline to week 26 in the rosiglitazone 2 mg (-0.7 percent; $p=0.0052$) and 4 mg (-1.2 percent; $p=0.0008$) groups, but increased in the placebo group (+0.3 percent; $p=0.2651$). Mean FBG levels also improved significantly with metformin plus rosiglitazone therapy in a dose-dependent manner compared with placebo ($p<0.0019$). The proportion of patients with one or more adverse events was similar across all three groups, with no cases of hepatotoxicity.

In a double-blind, randomized, parallel-group study, 766 subjects with a baseline metformin dose of 1,000 mg/day were randomized to receive either rosiglitazone 4 mg daily (4 mg/1,000 mg) or an additional 500 mg/day of metformin.¹¹² Increases in the study medications to maximum doses were performed after eight weeks. After 24 weeks, rosiglitazone 8 mg/metformin 1,000 mg was at least as effective as 2,000 mg/day of metformin in improving HbA1c with mean reductions of -0.93 and -0.71 percent, respectively, from baseline in subjects that completed the study. In addition, a higher percentage of subjects in the rosiglitazone/metformin group achieved HbA1c <7 percent (58.1 versus 48.4 percent). The percentage of subjects experiencing a gastrointestinal side effect was 27.9 and 38.7 percent for the rosiglitazone/metformin and metformin groups, respectively.

META-ANALYSES

pioglitazone (Actos)

To systematically evaluate the effect of pioglitazone on ischemic cardiovascular events, a database containing individual patient-level time-to-event data collected during pioglitazone clinical trials was

transferred from the drug's manufacturer for independent analysis. Trials were included if they were randomized, double-blinded, and controlled with placebo or active comparator.¹¹³ The primary outcome was a composite of death, myocardial infarction, or stroke. Secondary outcome measures included the incidence of serious heart failure. Data from a total of 19 trials, enrolling 16,390 patients, were combined by means of a fixed-effects model. Study drug treatment duration ranged from four months to 3.5 years. The primary outcome occurred in 375 of 8,554 patients (4.4 percent) receiving pioglitazone and 450 of 7,836 patients (5.7 percent) receiving control therapy (hazard ratio [HR], 0.82; 95% CI, 0.72-0.94; $p=0.005$). Individual components of the primary endpoint were all reduced by a similar magnitude with pioglitazone treatment, with HRs ranging from 0.80 to 0.92. Serious heart failure was reported in 200 (2.3 percent) of the pioglitazone (Actos)-treated patients and 139 (1.8 percent) of the control patients (HR, 1.41; 95% CI, 1.14-1.76; $p=0.002$). Serious heart failure is increased by pioglitazone, although without an associated increase in mortality.

pioglitazone (Actos) and rosiglitazone (Avandia)

A systematic review and meta-analysis of seven randomized, double-blind clinical trials of drug-related congestive heart failure in patients given TZDs (either rosiglitazone or pioglitazone) was performed.¹¹⁴ The main outcome measures were development of congestive heart failure and the risk of cardiovascular death. Of the 20,191 patients, 360 who had either prediabetes or type 2 diabetes had congestive heart failure events (214 with TZDs and 146 with comparators). Results showed no heterogeneity of effects across studies, which indicated a class effect for TZDs. Compared with controls, patients given TZDs had increased risk for development of congestive heart failure across a wide background of cardiac risk (relative risk 1.72; $p=0.002$). By contrast, the risk of cardiovascular death was not increased with either of the two TZDs (0.93; $p=0.68$).

rosiglitazone (Avandia)

Published literature, the Food and Drug Administration website, and a clinical trials registry maintained by the drug manufacturer were searched for studies with the following criteria: study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes.¹¹⁵ The inclusion criteria were met by 42 studies. All occurrences of myocardial infarction and death from cardiovascular causes were tabulated. Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline HbA1c was approximately 8.2 percent. Compared to the control group, the odds ratio for the rosiglitazone group for myocardial infarction was 1.43 (95% CI, 1.03 to 1.98; $p=0.03$), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; $p=0.06$).

TZDs and bone loss

A meta-analysis was conducted in patients with type 2 diabetes to confirm the effects of TZDs on bone are a drug class effect.¹¹⁶ PPAR- γ activation with TZDs leads to unbalanced bone remodeling: bone resorption increases and bone formation decreases. Risk factors for development of TZD-induced secondary osteoporosis are gender (women), age (elderly), and duration of treatment.

SUMMARY

As seen in the clinical trials, pioglitazone (Actos) and rosiglitazone (Avandia) are capable of lowering HbA1c by 1 to 1.5 percentage points when used as monotherapy in the treatment of type 2 diabetes. In combination with other agents used to lower blood glucose levels, including metformin and glimepiride, the level of HbA1c lowering is approximately an additional one percent.

In measuring the ability of pioglitazone and rosiglitazone to reduce other markers such as FPG, reductions of 40 to 60 mg/dL are possible with monotherapy, according to clinical trials. In combination with other antidiabetic agents, additional decreases of 35 to 50 mg/dL are seen.

Due to elevated risk of cardiovascular events, use of rosiglitazone and rosiglitazone-containing medicines has been significantly restricted. The FDA has announced that use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer.

The addition of combination products with metformin or glimepiride will allow more convenient administration for patients who require both drugs, but with added precautions for their use. Comparative data with these agents are limited and only include ingredient comparisons to the fixed-dose combination products.

REFERENCES

- 1 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 2 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 3 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 4 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 5 Actoplus Met [package insert]. Deerfield, IL; Takeda Pharmaceuticals; May 2012.
- 6 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 7 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 8 Diabetes Statistics. <http://www.diabetes.org/diabetes-statistics.jsp>. Accessed October 4, 2012.
- 9 Skyler JS. Glucose control in type 2 diabetes mellitus. *Ann Intern Med.* 1997; 127:837-839.
- 10 DeFronzo RA. The triumvirate: β -cell, muscle, liver: A collusion responsible for NIDDM. *Diabetes.* 1988; 37:667-687.
- 11 Available at: <http://care.diabetesjournals.org/site/misc/DC09-9033.pdf>. Accessed October 4, 2012.
- 12 American Diabetes Association Position Statement: Standards of Medical Care in Diabetes-2012. *Diabetes Care* 2012;35(S1):S11-S63. Available at: http://care.diabetesjournals.org/content/35/Supplement_1. Accessed October 4, 2012.
- 13 Rodbard HW, Jellinger PS, Bloomgarden ZT, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. *Endocr Pract.* 2009; 15:540-559.
- 14 Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract.*; 2011; 17(2):1-53.
- 15 Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012; 35: 1364-1379. Available at: <http://care.diabetesjournals.org/content/35/6/1364.full.pdf+html>. Accessed October 4, 2012.
- 16 Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract.*; 2011; 17(2):1-53.
- 17 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 18 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 19 Actoplus Met /Actoplus Met XR[package insert]. Deerfield, IL; Takeda Pharmaceuticals; July2011.
- 20 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 21 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 22 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 23 Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract.*; 2011; 17(2):1-53.
- 24 Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in Type 2 Diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012; 35: 1364-1379. Available at: <http://care.diabetesjournals.org/content/35/6/1364.full.pdf+html>. Accessed October 4, 2012.
- 25 Amaryl [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; July 2009.
- 26 Glucophage/GlucoPhage XR [package insert]. Princeton, NJ; Bristol-Myers Squibb; January 2009.
- 27 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 28 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 29 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; August 2011.

- 30 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 31 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 32 Duetact [package insert]. Deerfield, IL; Takeda; August 2011.
- 33 Actos [package insert]. Deerfield, IL; Takeda; August 2011.
- 34 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 35 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 36 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 37 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 38 Duetact [package insert]. Deerfield, IL; Takeda; August 2011.
- 39 Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201418.htm>. Accessed October 4, 2012.
- 40 Available at: <http://circ.ahajournals.org/content/early/2010/02/23/CIR.0b013e3181d34114.citation>. Accessed October 4, 2012.
- 41 Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201418.htm>. Accessed October 4, 2012.
- 42 Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm>. Accessed October 4, 2012.
- 43 <http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm#sa>. Accessed October 4, 2012.
- 44 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 45 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 46 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 47 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 48 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 49 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 50 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 51 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 52 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 53 Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes. An analysis from a diabetes outcome progression trial (ADOPT). *Diabetes Care*. 2008; 31(5):845-851.
- 54 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 55 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 56 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011..
- 57 Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959>. Accessed October 4, 2012.
- 58 Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm>. Accessed October 4, 2012.
- 59 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 60 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 61 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 62 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 63 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 64 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 65 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 66 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 67 Amaryl [package insert]. Bridgewater, NJ; Aventis Pharmaceuticals; July 2009.
- 68 Glucophage/Glucophage XR [package insert]. Princeton, NJ; Bristol-Myers Squibb; January 2009.
- 69 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 70 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 71 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 72 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 73 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 74 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 75 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 76 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 77 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 78 Actos [package insert]. Deerfield, IL; Takeda; July 2011.
- 79 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 80 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 81 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 82 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 83 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 84 American Diabetes Association Position Statement: Standards of Medical Care in Diabetes-2012. *Diabetes Care* 2012;35(S1):S11-S63. Available at: http://care.diabetesjournals.org/content/35/Supplement_1. Accessed October 4, 2012.
- 85 Handelsman Y, Mechanick JL, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract.*; 2011; 17(2):1-53.
- 86 Davidson JA, McMorn SO, Waterhouse BR, et al. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. *Clin Ther.* 2007; 29(9):1900-1914.
- 87 Actos [package insert]. Deerfield, IL; Takeda; July 2011.

- 88 Avandia [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2011.
- 89 Actoplus Met [package insert]. Deerfield, IL; Takeda Pharmaceuticals; May 2012.
- 90 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 91 Avandamet [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 92 Avandaryl [package insert]. Research Triangle Park, NC; GlaxoSmithKline, May 2011.
- 93 Duetact [package insert]. Deerfield, IL; Takeda; July 2011.
- 94 Actoplus Met/ Actoplus Met XR [package insert]. Deerfield, IL; Takeda Pharmaceuticals; July 2011.
- 95 Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. *Diabetes Care*. 2000; 23(11):1605-1611.
- 96 Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. *Coron Artery Dis*. 2001; 12(5):413-423.
- 97 Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. *Horm Metab Res*. 2002; 34(10):589-595.
- 98 Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. *Int J Clin Pract*. 2002; 56(4):251-257.
- 99 Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. *Diabetes Obes Metab*. 2007; 9(4):512-520.
- 100 Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. *Curr Med Res Opin*. 2009; 25(12):2915-23.
- 101 Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled parallel-group trial. *Clin Ther*. 2004; 26(5):744-754.
- 102 Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther*. 2005; 27(10):1535-1547.
- 103 Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. *Diabet Med*. 2000; 17(4):287-294.
- 104 Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. *Diabetes Care*. 2001; 24(2):308-315.
- 105 Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2001; 86(1):280-288.
- 106 Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. *Diabetologia*. 2000; 43(3):278-284.
- 107 Dailey GE 3rd, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: randomized, double-blind trial. *Am J Med*. 2004; 116(4):276-278.
- 108 Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. Sulphonylurea Titration (RESULT) study. *Diabetes Obes Metab*. 2006; 8(1):49-57.
- 109 Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. *Diabetes Care*. 2001; 24(7):1226-1232.
- 110 Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. *JAMA*. 2000; 283(13):1695-1702.
- 111 Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. *Diabetes Metab Res Rev*. 2002; 18(2):127-134.
- 112 Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. *Curr Med Res Opin*. 2005; 21(12):2029-2035.
- 113 Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007; 298(10):1180-1188.
- 114 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet*. 2007; 370(9593):1129-1136.
- 115 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007; 356(24):2457-2471.
- 116 Lecka-Czernik B. Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. *Curr Osteoporos Rep*. 2010; 8(4): 178–184.